Table of Contents Author Guidelines Submit a Manuscript

A corrigendum for this article has been published. To view the corrigendum, please click here.

International Journal of Endocrinology
Volume 2014 (2014), Article ID 690783, 26 pages
Review Article

The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes

1Division of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128 Rome, Italy
2Division of Bone and Mineral Diseases, Washington University in St Louis, St Louis, MO, USA
3Centre for Diabetes, The Blizard Building, Barts and The London School of Medicine, Queen Mary, University of London, London, UK
4Division of Endocrinology, Mount Sinai School of Medicine, New York, USA

Received 30 December 2013; Accepted 11 June 2014; Published 16 July 2014

Academic Editor: Debra Waters

Copyright © 2014 Nicola Napoli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Bone fragility has emerged as a new complication of diabetes. Several mechanisms in diabetes may influence bone homeostasis by impairing the action between osteoblasts, osteoclasts, and osteocytes and/or changing the structural properties of the bone tissue. Some of these mechanisms can potentially alter the fate of mesenchymal stem cells, the initial precursor of the osteoblast. In this review, we describe the main factors that impair bone health in diabetic patients and their clinical impact.